{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:25:05Z","timestamp":1792959905190,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T00:00:00Z","timestamp":1757721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Emily's Entourage"},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#2\/2023"],"award-info":[{"award-number":["FFC#2\/2023"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/04046\/2025"],"award-info":[{"award-number":["UID\/04046\/2025"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["H2020-SC1-2017-755021"],"award-info":[{"award-number":["H2020-SC1-2017-755021"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["EC HORIZON\u2013MSCA-2023-DN-JD- 101120108"],"award-info":[{"award-number":["EC HORIZON\u2013MSCA-2023-DN-JD- 101120108"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FARINH24G0"],"award-info":[{"award-number":["FARINH24G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Diagn Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40291-025-00806-5","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:11:07Z","timestamp":1757769067000},"page":"111-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Personalized Medicine in Cystic Fibrosis: Characterization of Eight Rare CFTR Variants in Intestinal Organoids and Cellular Models"],"prefix":"10.1007","volume":"30","author":[{"given":"Violeta","family":"Railean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia S.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Pankonien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia S.","family":"Ramalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris A. L.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Dou\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Castanhinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Roda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5467-1710","authenticated-orcid":false,"given":"Carlos M.","family":"Farinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"806_CR1","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245:1066\u201373.","journal-title":"Science"},{"key":"806_CR2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","volume":"79","author":"DN Sheppard","year":"1999","unstructured":"Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev. 1999;79:S23-45.","journal-title":"Physiol Rev"},{"key":"806_CR3","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1056\/NEJMra043184","volume":"352","author":"SM Rowe","year":"2005","unstructured":"Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992\u20132001.","journal-title":"N Engl J Med"},{"key":"806_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","volume":"74","author":"V Saint-Criq","year":"2017","unstructured":"Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci. 2017;74:93\u2013115.","journal-title":"Cell Mol Life Sci"},{"key":"806_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1183\/09031936.03.00057003","volume":"23","author":"RC Boucher","year":"2004","unstructured":"Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J. 2004;23:146\u201358.","journal-title":"Eur Respir J"},{"key":"806_CR6","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1113\/jphysiol.2008.164970","volume":"587","author":"HC Chan","year":"2009","unstructured":"Chan HC, Ruan YC, He Q, Chen MH, Chen H, Xu WM, et al. The cystic fibrosis transmembrane conductance regulator in reproductive health and disease. J Physiol. 2009;587:2187\u201395.","journal-title":"J Physiol"},{"issue":"Suppl. 2","key":"806_CR7","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","volume":"16","author":"VK Singh","year":"2017","unstructured":"Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic fibrosis. J Cyst Fibros. 2017;16(Suppl. 2):S70\u20138.","journal-title":"J Cyst Fibros"},{"key":"806_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1365-2796.2006.01744.x","volume":"261","author":"RC Boucher","year":"2007","unstructured":"Boucher RC. Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med. 2007;261:5\u201316.","journal-title":"J Intern Med"},{"key":"806_CR9","unstructured":"Cystic Fibrosis Mutation Database. http:\/\/www.genet.sickkids.on.ca\/. Accessed 16 Jan 2023."},{"key":"806_CR10","unstructured":"Patient Registry. CFF 2022. https:\/\/www.cff.org\/medical-professionals\/patient-registry. Accessed 1 July 2024."},{"key":"806_CR11","unstructured":"Patient Registry 2022. ECFS. https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports. Accessed 1 July 2024."},{"key":"806_CR12","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","volume":"4","author":"K De Boeck","year":"2016","unstructured":"De Boeck K, Amaral MD. Progress in therapies for cystic fibrosis. Lancet Respir Med. 2016;4:662\u201374.","journal-title":"Lancet Respir Med"},{"issue":"1341\u20135","key":"806_CR13","first-page":"e699","volume":"58","author":"CA Schram","year":"2012","unstructured":"Schram CA. Atypical cystic fibrosis: identification in the primary care setting. Can Fam Physician. 2012;58(1341\u20135):e699-704.","journal-title":"Can Fam Physician"},{"key":"806_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/rr82","volume":"2","author":"PG Noone","year":"2001","unstructured":"Noone PG, Knowles MR. \u201cCFTR-opathies\u201d: disease phenotypes associated with cystic fibrosis transmembrane regulator gene mutations. Respir Res. 2001;2:328\u201332.","journal-title":"Respir Res"},{"key":"806_CR15","unstructured":"CFTR2. CFTR2 database. http:\/\/www.cftr2.org. Accessed 24 June 2024."},{"key":"806_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jcf.2008.03.009","volume":"7","author":"C Castellani","year":"2008","unstructured":"Castellani C, Cuppens H, Macek M, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008;7:179\u201396.","journal-title":"J Cyst Fibros"},{"key":"806_CR17","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor F, Hadida S, Grootenhuis PDJ, Burton B, Cao D, Neuberger T, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009;106:18825\u201330.","journal-title":"Proc Natl Acad Sci USA"},{"key":"806_CR18","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","volume":"363","author":"FJ Accurso","year":"2010","unstructured":"Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363:1991\u20132003.","journal-title":"N Engl J Med"},{"key":"806_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","volume":"13","author":"F Van Goor","year":"2014","unstructured":"Van Goor F, Yu H, Burton B, Hoffman BJ. Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2014;13:29\u201336.","journal-title":"J Cyst Fibros"},{"key":"806_CR20","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, et al. VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med. 2018;379:1612\u201320.","journal-title":"N Engl J Med"},{"key":"806_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG, Mall MA, D\u0159ev\u00ednek P, Lands LC, McKone EF, Polineni D, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809\u201319.","journal-title":"N Engl J Med"},{"key":"806_CR22","unstructured":"Relat\u00f3rios de avalia\u00e7\u00e3o de financiamento p\u00fablico. https:\/\/www.infarmed.pt\/web\/infarmed\/relatorios-de-avaliacao-de-financiamento-publico. Accessed 25 June 2024."},{"key":"806_CR23","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","volume":"21","author":"J Guo","year":"2022","unstructured":"Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cyst Fibros. 2022;21:456\u201362.","journal-title":"J Cyst Fibros"},{"issue":"4","key":"806_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","volume":"23","author":"H Bihler","year":"2024","unstructured":"Bihler H, Sivachenko A, Millen L, Bhatt P, Patel AT, Chin J, et al. In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis. J Cyst Fibros. 2024;23(4):664\u201375.","journal-title":"J Cyst Fibros"},{"key":"806_CR25","unstructured":"Amaral MD, Pankonien I. Theranostics vs theratyping or theranostics plus theratyping? J Cystic Fibrosis. 2024. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S156919932401782X. Accessed 14 Nov 2024."},{"key":"806_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad8278","volume":"8","author":"JF Dekkers","year":"2016","unstructured":"Dekkers JF, Berkers G, Kruisselbrink E, Vonk A, De Jonge HR, Janssens HM, et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016;8: 344ra84.","journal-title":"Sci Transl Med"},{"key":"806_CR27","doi-asserted-by":"publisher","first-page":"1902426","DOI":"10.1183\/13993003.02426-2019","volume":"57","author":"AS Ramalho","year":"2021","unstructured":"Ramalho AS, F\u00fcrstov\u00e1 E, Vonk AM, Ferrante M, Verfaillie C, Dupont L, et al. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis. Eur Respir J. 2021;57:1902426.","journal-title":"Eur Respir J"},{"key":"806_CR28","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12931-023-02516-0","volume":"24","author":"S Lo Cicero","year":"2023","unstructured":"Lo Cicero S, Castelli G, Blacon\u00e0 G, Bruno SM, Sette G, Pigliucci R, et al. L1077p CFTR pathogenic variant function rescue by elexacaftor-tezacaftor-ivacaftor in cystic fibrosis patient-derived air-liquid interface (ALI) cultures and organoids: in vitro guided personalized therapy of non-F508del patients. Respir Res. 2023;24:217.","journal-title":"Respir Res"},{"key":"806_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.jcf.2024.04.014","volume":"23","author":"MC Bierlaagh","year":"2024","unstructured":"Bierlaagh MC, Ramalho AS, Silva IAL, Vonk AM, van den Bor RM, van Mourik P, et al. Repeatability and reproducibility of the forskolin-induced swelling (FIS) assay on intestinal organoids from people with cystic fibrosis. J Cyst Fibros. 2024;23:693\u2013702.","journal-title":"J Cyst Fibros"},{"issue":"Suppl. 1","key":"806_CR30","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jcf.2019.11.002","volume":"19","author":"E de Poel","year":"2020","unstructured":"de Poel E, Lefferts JW, Beekman JM. Intestinal organoids for cystic fibrosis research. J Cyst Fibros. 2020;19(Suppl. 1):S60\u20134.","journal-title":"J Cyst Fibros"},{"key":"806_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165905","volume":"1866","author":"IAL Silva","year":"2020","unstructured":"Silva IAL, Dou\u0161ov\u00e1 T, Ramalho S, Centeio R, Clarke LA, Railean V, et al. Organoids as a personalized medicine tool for ultra-rare mutations in cystic fibrosis: the case of S955P and 1717\u20132A>G. Biochim Biophys Acta Mol Basis Dis. 2020;1866: 165905.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"806_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1155705","volume":"10","author":"V Railean","year":"2023","unstructured":"Railean V, Rodrigues CS, Ramalho SS, Silva IAL, Bartosch J, Farinha CM, et al. Personalized medicine: function of CFTR variant p.Arg334Trp is rescued by currently available CFTR modulators. Front Mol Biosci. 2023;10: 1155705.","journal-title":"Front Mol Biosci"},{"key":"806_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050421","volume":"11","author":"IAL Silva","year":"2021","unstructured":"Silva IAL, Railean V, Duarte A, Amaral MD. Personalized medicine based on nasal epithelial cells: comparative studies with rectal biopsies and intestinal organoids. J Pers Med. 2021;11: 421.","journal-title":"J Pers Med"},{"issue":"14","key":"806_CR34","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.86581","volume":"1","author":"CM Sabusap","year":"2016","unstructured":"Sabusap CM, Wang W, McNicholas CM, Chung WJ, Fu L, Wen H, et al. Analysis of cystic fibrosis-associated P67L CFTR illustrates barriers to personalized therapeutics for orphan diseases. JCI Insight. 2016;1(14): e86581.","journal-title":"JCI Insight"},{"key":"806_CR35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijms23010024","volume":"23","author":"SS Ramalho","year":"2021","unstructured":"Ramalho SS, Silva IAL, Amaral MD, Farinha CM. Rare trafficking CFTR mutations involve distinct cellular retention machineries and require different rescuing strategies. Int J Mol Sci. 2021;23:24.","journal-title":"Int J Mol Sci"},{"key":"806_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070643","volume":"11","author":"G Veit","year":"2021","unstructured":"Veit G, Velkov T, Xu H, Vadeboncoeur N, Bilodeau L, Matouk E, et al. A precision medicine approach to optimize modulator therapy for rare CFTR folding mutants. J Pers Med. 2021;11: 643.","journal-title":"J Pers Med"},{"key":"806_CR37","doi-asserted-by":"publisher","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","volume":"62","author":"E Dreano","year":"2023","unstructured":"Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, et al. Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription. Eur Respir J. 2023;62:2300110.","journal-title":"Eur Respir J"},{"key":"806_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/jpm10020040","volume":"10","author":"O Laselva","year":"2020","unstructured":"Laselva O, Moraes TJ, He G, Bartlett C, Sz\u00e0rics I, Ouyang H, et al. The CFTR mutation c.3453G > C (D1152H) confers an anion selectivity defect in primary airway tissue that can be rescued by ivacaftor. J Pers Med. 2020;10:40.","journal-title":"J Pers Med."},{"key":"806_CR39","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jcf.2025.02.008","volume":"24","author":"J Conti","year":"2025","unstructured":"Conti J, Angyal D, Kleinfelder K, Latorre RV, Calicchia M, Farinazzo A, et al. Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers. J Cyst Fibros. 2025;24:552\u201361.","journal-title":"J Cyst Fibros"},{"key":"806_CR40","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1002\/ppul.27211","volume":"59","author":"V Fainardi","year":"2024","unstructured":"Fainardi V, Cresta F, Sorio C, Melotti P, Pesce E, Deolmi M, et al. Elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and rare mutations. Pediatr Pulmonol. 2024;59:3383\u201390.","journal-title":"Pediatr Pulmonol"},{"key":"806_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2020.100019","volume":"1","author":"AM Vonk","year":"2020","unstructured":"Vonk AM, van Mourik P, Ramalho AS, Silva IAL, Statia M, Kruisselbrink E, et al. Protocol for application, standardization and validation of the forskolin-induced swelling assay in Cystic fibrosis human colon organoids. STAR Protoc. 2020;1: 100019.","journal-title":"STAR Protoc."},{"key":"806_CR42","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1093\/bioinformatics\/btaa1073","volume":"36","author":"MC Hagemeijer","year":"2021","unstructured":"Hagemeijer MC, Vonk AM, Awatade NT, Silva IAL, Tischer C, Hilsenstein V, et al. An open-source high-content analysis workflow for CFTR function measurements using the forskolin-induced swelling assay. Bioinformatics. 2021;36:5686\u201394.","journal-title":"Bioinformatics"},{"issue":"2","key":"806_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jcf.2018.07.001","volume":"18","author":"NT Awatade","year":"2019","unstructured":"Awatade NT, Ramalho S, Silva IAL, Fel\u00edcio V, Botelho HM, de Poel E, et al. R560S: a class II CFTR mutation that is not rescued by current modulators. J Cyst Fibros. 2019;18(2):182\u20139.","journal-title":"J Cyst Fibros"},{"key":"806_CR44","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00018-018-2896-7","volume":"75","author":"S Canato","year":"2018","unstructured":"Canato S, Santos JD, Carvalho AS, Aloria K, Amaral MD, Matthiesen R, et al. Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation. Cell Mol Life Sci. 2018;75:4495\u2013509.","journal-title":"Cell Mol Life Sci"},{"key":"806_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1113\/jphysiol.2005.096669","volume":"569","author":"Z Bebok","year":"2005","unstructured":"Bebok Z, Collawn JF, Wakefield J, Parker W, Li Y, Varga K, et al. Failure of cAMP agonists to activate rescued \u0394F508 CFTR in CFBE41o- airway epithelial monolayers. J Physiol. 2005;569:601\u201315.","journal-title":"J Physiol"},{"key":"806_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ebiom.2014.12.005","volume":"2","author":"NT Awatade","year":"2015","unstructured":"Awatade NT, Uliyakina I, Farinha CM, Clarke LA, Mendes K, Sol\u00e9 A, et al. Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine. 2015;2:147\u201353.","journal-title":"EBioMedicine"},{"key":"806_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008889","volume":"6","author":"G Veit","year":"2014","unstructured":"Veit G, Avramescu RG, Perdomo D, Phuan P-W, Bagdany M, Apaja PM, et al. Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression. Sci Transl Med. 2014;6: 246ra97.","journal-title":"Sci Transl Med"},{"key":"806_CR48","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","volume":"26","author":"G Berkers","year":"2019","unstructured":"Berkers G, van Mourik P, Vonk AM, Kruisselbrink E, Dekkers JF, de Winter-de Groot KM, et al. Rectal organoids enable personalized treatment of cystic fibrosis. Cell Rep. 2019;26:1701-8.e3.","journal-title":"Cell Rep"},{"key":"806_CR49","doi-asserted-by":"publisher","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","volume":"57","author":"O Laselva","year":"2021","unstructured":"Laselva O, Bartlett C, Gunawardena TNA, Ouyang H, Eckford PDW, Moraes TJ, et al. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J. 2021;57:2002774.","journal-title":"Eur Respir J"},{"key":"806_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100598","volume":"296","author":"CM Sabusap","year":"2021","unstructured":"Sabusap CM, Joshi D, Simhaev L, Oliver KE, Senderowitz H, van Willigen M, et al. The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue. J Biol Chem. 2021;296: 100598.","journal-title":"J Biol Chem"},{"key":"806_CR51","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000257426","volume":"24","author":"AS Ramalho","year":"2009","unstructured":"Ramalho AS, Lewandowska MA, Farinha CM, Mendes F, Gon\u00e7alves J, Barreto C, et al. Deletion of CFTR translation start site reveals functional isoforms of the protein in CF patients. Cell Physiol Biochem. 2009;24:335\u201346.","journal-title":"Cell Physiol Biochem"},{"key":"806_CR52","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/humu.20721","volume":"29","author":"GG Gen\u00e9","year":"2008","unstructured":"Gen\u00e9 GG, Llobet A, Larriba S, de Semir D, Mart\u00ednez I, Escalada A, et al. N-terminal CFTR missense variants severely affect the behavior of the CFTR chloride channel. Hum Mutat. 2008;29:738\u201349.","journal-title":"Hum Mutat"},{"key":"806_CR53","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1074\/jbc.M508131200","volume":"281","author":"A Jurkuvenaite","year":"2006","unstructured":"Jurkuvenaite A, Varga K, Nowotarski K, Kirk KL, Sorscher EJ, Li Y, et al. Mutations in the amino terminus of the cystic fibrosis transmembrane conductance regulator enhance endocytosis. J Biol Chem. 2006;281:3329\u201334.","journal-title":"J Biol Chem"},{"key":"806_CR54","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1074\/jbc.274.6.3602","volume":"274","author":"LS Prince","year":"1999","unstructured":"Prince LS, Peter K, Hatton SR, Zaliauskiene L, Cotlin LF, Clancy JP, et al. Efficient endocytosis of the cystic fibrosis transmembrane conductance regulator requires a tyrosine-based signal. J Biol Chem. 1999;274:3602\u20139.","journal-title":"J Biol Chem"},{"key":"806_CR55","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jcf.2011.08.009","volume":"11","author":"L Spicuzza","year":"2012","unstructured":"Spicuzza L, Sciuto C, Di Dio L, Mattina T, Leonardi S, del Giudice MM, et al. Mild cystic fibrosis in patients with the rare P5L CFTR mutation. J Cyst Fibros. 2012;11:30\u20133.","journal-title":"J Cyst Fibros"},{"key":"806_CR56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12890-019-0840-8","volume":"19","author":"M Welsner","year":"2019","unstructured":"Welsner M, Stra\u00dfburg S, Taube C, Sutharsan S. Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H\u20137T: a case report. BMC Pulm Med. 2019;19:76.","journal-title":"BMC Pulm Med"},{"key":"806_CR57","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13073-014-0060-z","volume":"6","author":"JE Castillo-Fernandez","year":"2014","unstructured":"Castillo-Fernandez JE, Spector TD, Bell JT. Epigenetics of discordant monozygotic twins: implications for disease. Genome Med. 2014;6:60.","journal-title":"Genome Med"},{"key":"806_CR58","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1399-0004.2011.01804.x","volume":"82","author":"R Sebro","year":"2012","unstructured":"Sebro R, Levy H, Schneck K, Dimmock D, Raby BA, Cannon CL, et al. Cystic fibrosis mutations for p. F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. Clin Genet. 2012;82:546\u201351.","journal-title":"Clin Genet"},{"key":"806_CR59","doi-asserted-by":"publisher","first-page":"14205","DOI":"10.3390\/ijms232214205","volume":"23","author":"J M\u00e9sin\u00e8le","year":"2022","unstructured":"M\u00e9sin\u00e8le J, Ruffin M, Guillot L, Corvol H. Modifier factors of cystic fibrosis phenotypes: a focus on modifier genes. Int J Mol Sci. 2022;23:14205.","journal-title":"Int J Mol Sci"},{"key":"806_CR60","doi-asserted-by":"publisher","first-page":"14995","DOI":"10.1074\/jbc.271.25.14995","volume":"271","author":"DN Sheppard","year":"1996","unstructured":"Sheppard DN, Travis SM, Ishihara H, Welsh MJ. Contribution of proline residues in the membrane-spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function. J Biol Chem. 1996;271:14995\u20135001.","journal-title":"J Biol Chem"},{"key":"806_CR61","first-page":"381","volume":"9","author":"WC Wigley","year":"2002","unstructured":"Wigley WC, Corboy MJ, Cutler TD, Thibodeau PH, Oldan J, Lee MG, et al. A protein sequence that can encode native structure by disfavoring alternate conformations. Nat Struct Biol. 2002;9:381\u20138.","journal-title":"Nat Struct Biol"},{"key":"806_CR62","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/humu.20156","volume":"25","author":"J Clain","year":"2005","unstructured":"Clain J, Lehmann-Che J, Dugu\u00e9p\u00e9roux I, Arous N, Girodon E, Legendre M, et al. Misprocessing of the CFTR protein leads to mild cystic fibrosis phenotype. Hum Mutat. 2005;25:360\u201371.","journal-title":"Hum Mutat"},{"key":"806_CR63","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.201800172","volume":"2","author":"M van Willigen","year":"2019","unstructured":"van Willigen M, Vonk AM, Yeoh HY, Kruisselbrink E, Kleizen B, van der Ent CK, et al. Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants. Life Sci Alliance. 2019;2: e201800172.","journal-title":"Life Sci Alliance."},{"key":"806_CR64","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/362160a0","volume":"362","author":"DN Sheppard","year":"1993","unstructured":"Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-disease-form Cl- channels with altered pore properties. Nature. 1993;362:160\u20134.","journal-title":"Nature"},{"key":"806_CR65","doi-asserted-by":"publisher","first-page":"19810","DOI":"10.1038\/s41598-021-99184-1","volume":"11","author":"CA Shaughnessy","year":"2021","unstructured":"Shaughnessy CA, Zeitlin PL, Bratcher PE. Elexacaftor is a CFTR potentiator and acts synergistically with ivacaftor during acute and chronic treatment. Sci Rep. 2021;11:19810.","journal-title":"Sci Rep"},{"key":"806_CR66","doi-asserted-by":"publisher","first-page":"11941","DOI":"10.1074\/jbc.270.20.11941","volume":"270","author":"TP Carroll","year":"1995","unstructured":"Carroll TP, Morales MM, Fulmer SB, Allen SS, Flotte TR, Cutting GR, et al. Alternate translation initiation codons can create functional forms of cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1995;270:11941\u20136.","journal-title":"J Biol Chem"},{"key":"806_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043211","author":"S Zacarias","year":"2023","unstructured":"Zacarias S, Batista MSP, Ramalho SS, Victor BL, Farinha CM. Rescue of rare CFTR trafficking mutants highlights a structural location-dependent pattern for correction. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms24043211.","journal-title":"Int J Mol Sci"},{"key":"806_CR68","doi-asserted-by":"publisher","first-page":"35896","DOI":"10.1074\/jbc.M205644200","volume":"277","author":"ACV DeCarvalho","year":"2002","unstructured":"DeCarvalho ACV, Gansheroff LJ, Teem JL. Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508. J Biol Chem. 2002;277:35896\u2013905.","journal-title":"J Biol Chem"},{"key":"806_CR69","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1038\/s41467-020-18101-8","volume":"11","author":"H Shishido","year":"2020","unstructured":"Shishido H, Yoon JS, Yang Z, Skach WR. Cftr trafficking mutations disrupt cotranslational protein folding by targeting biosynthetic intermediates. Nat Commun. 2020;11:4258.","journal-title":"Nat Commun"},{"key":"806_CR70","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/cbic.201500620","volume":"17","author":"M Lopes-Pacheco","year":"2016","unstructured":"Lopes-Pacheco M, Sabirzhanova I, Rapino D, Morales MM, Guggino WB, Cebotaru L. Correctors rescue CFTR mutations in nucleotide-binding domain 1 (NBD1) by modulating proteostasis. ChemBioChem. 2016;17:493\u2013505.","journal-title":"ChemBioChem"},{"key":"806_CR71","doi-asserted-by":"publisher","first-page":"27493","DOI":"10.1074\/jbc.271.44.27493","volume":"271","author":"FS Seibert","year":"1996","unstructured":"Seibert FS, Linsdell P, Loo TW, Hanrahan JW, Riordan JR, Clarke DM. Cytoplasmic loop three of cystic fibrosis transmembrane conductance regulator contributes to regulation of chloride channel activity. J Biol Chem. 1996;271:27493\u20139.","journal-title":"J Biol Chem"},{"key":"806_CR72","doi-asserted-by":"publisher","first-page":"1062766","DOI":"10.3389\/fped.2022.1062766","volume":"10","author":"KM Allan","year":"2022","unstructured":"Allan KM, Astore MA, Fawcett LK, Wong SL, Chen P-C, Griffith R, et al. S945L-CFTR molecular dynamics, functional characterization and tezacaftor\/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models. Front Pediatr. 2022;10:1062766.","journal-title":"Front Pediatr"},{"key":"806_CR73","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/(SICI)1098-1004(1997)9:4<332::AID-HUMU5>3.0.CO;2-7","volume":"9","author":"WE Highsmith","year":"1997","unstructured":"Highsmith WE, Burch LH, Zhou Z, Olsen JC, Strong TV, Smith T, et al. Identification of a splice site mutation (2789 +5 G > A) associated with small amounts of normal CFTR mRNA and mild cystic fibrosis. Hum Mutat. 1997;9:332\u20138.","journal-title":"Hum Mutat"},{"key":"806_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-5793(98)01042-4","volume":"437","author":"A Vankeerberghen","year":"1998","unstructured":"Vankeerberghen A, Wei L, Teng H, Jaspers M, Cassiman JJ, Nilius B, et al. Characterization of mutations located in exon 18 of the CFTR gene. FEBS Lett. 1998;437:1\u20134.","journal-title":"FEBS Lett"},{"key":"806_CR75","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1399-0004.2009.01294.x","volume":"77","author":"P-R Burgel","year":"2010","unstructured":"Burgel P-R, Fajac I, Hubert D, Grenet D, Stremler N, Roussey M, et al. Non-classic cystic fibrosis associated with D1152H CFTR mutation. Clin Genet. 2010;77:355\u201364.","journal-title":"Clin Genet"},{"key":"806_CR76","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ppul.20343","volume":"41","author":"H Mussaffi","year":"2006","unstructured":"Mussaffi H, Prais D, Mei-Zahav M, Blau H. Cystic fibrosis mutations with widely variable phenotype: the D1152H example. Pediatr Pulmonol. 2006;41:250\u20134.","journal-title":"Pediatr Pulmonol"},{"key":"806_CR77","doi-asserted-by":"publisher","first-page":"C866","DOI":"10.1152\/ajpcell.00404.2009","volume":"298","author":"N Pedemonte","year":"2010","unstructured":"Pedemonte N, Tomati V, Sondo E, Galietta LJV. Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol. 2010;298:C866\u201374.","journal-title":"Am J Physiol Cell Physiol"},{"key":"806_CR78","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004376","volume":"10","author":"J LaRusch","year":"2014","unstructured":"LaRusch J, Jung J, General IJ, Lewis MD, Park HW, Brand RE, et al. Mechanisms of CFTR functional variants that impair regulated bicarbonate permeation and increase risk for pancreatitis but not for cystic fibrosis. PLoS Genet. 2014;10: e1004376.","journal-title":"PLoS Genet"},{"key":"806_CR79","doi-asserted-by":"publisher","first-page":"22891","DOI":"10.1074\/jbc.M115.665125","volume":"290","author":"V Corradi","year":"2015","unstructured":"Corradi V, Vergani P, Tieleman DP. Cystic fibrosis transmembrane conductance regulator (CFTR). J Biol Chem. 2015;290:22891\u2013906.","journal-title":"J Biol Chem"},{"key":"806_CR80","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/BF00210305","volume":"96","author":"M Desgeorges","year":"1995","unstructured":"Desgeorges M, Rodier M, Piot M, Demaille J, Claustres M. Four adult patients with the missense mutation L206W and a mild cystic fibrosis phenotype. Hum Genet. 1995;96:717\u201320.","journal-title":"Hum Genet"},{"key":"806_CR81","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1093\/hmg\/2.10.1741","volume":"2","author":"M Chill\u00f3n","year":"1993","unstructured":"Chill\u00f3n M, Casals T, Nunes V, Gim\u00e9nez J, P\u00e9rez Ruiz E, Estivill X. Identification of a new missense mutation (P205S) in the first transmembrane domain of the CFTR gene associated with a mild cystic fibrosis phenotype. Hum Mol Genet. 1993;2:1741\u20132.","journal-title":"Hum Mol Genet"},{"key":"806_CR82","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/GIM.0b013e31818e55a2","volume":"10","author":"SM Moskowitz","year":"2008","unstructured":"Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, et al. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med. 2008;10:851\u201368.","journal-title":"Genet Med"},{"key":"806_CR83","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1378\/chest.12-1430","volume":"143","author":"AG Durmowicz","year":"2013","unstructured":"Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013;143:14\u20138.","journal-title":"Chest"},{"key":"806_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13154491","volume":"13","author":"HM Winiarska","year":"2024","unstructured":"Winiarska HM, Springer D, Wojta\u015b F, Wysocka E, Cofta S. CFTR modulators therapy efficacy in reducing cystic fibrosis (CF) exacerbation and improving selected spirometry parameters: a real-life study in a single-centre Polish population. J Clin Med. 2024;13: 4491.","journal-title":"J Clin Med"}],"container-title":["Molecular Diagnosis &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40291-025-00806-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40291-025-00806-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:03:20Z","timestamp":1769587400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40291-025-00806-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,13]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["806"],"URL":"https:\/\/doi.org\/10.1007\/s40291-025-00806-5","relation":{},"ISSN":["1177-1062","1179-2000"],"issn-type":[{"value":"1177-1062","type":"print"},{"value":"1179-2000","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,13]]},"assertion":[{"value":"29 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by FCT|FCCN (b-on). The work was supported by the UID\/04046\/2025 centre grant (to BioISI), from FCT\/MCTES Portugal, and research grants: \u201cHIT-CF\u201d (H2020-SC1-2017-755021) (to MDA), \u201cORGESTRA\u201d (EC HORIZON\u2013MSCA-2023-DN-JD- 101120108) [to MDA], both from European Union, FFC#2\/2023 (to CMF) from Fondazione Fibrosi Cistica Ricerca, grant FARINH24G0 from the Cystic Fibrosis Foundation (to CMF), and a grant from Emily\u2019s Entourage (to CMF). CR, IP, and VR were supported by FCT - Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia, I.P. (Portugal) by project references, UI\/BD\/153053\/2022, DL57\/2016\/CP1479\/CT0013, 2021.06718.BD, and DOI identifiers,\n                      \n                      ,\n                      \n                      ,\n                      \n                      , respectively, and also supported by FCT SSR by fellowship SFRH\/BD\/142857\/2018 from the BioSys PhD programme PD\/00065\/2012. The Faculty of Sciences of the University of Lisboa\u2019s Microscopy Facility is a node of the Portuguese Platform of BioImaging, reference PPBI-POCI-01-0145-FEDER-022122.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Violeta Railean, Cl\u00e1udia S. Rodrigues, Ines Pankonien, Sofia S. Ramalho, Iris A.L. Silva, Tereza Dou\u0161ov\u00e1, Susana Castanhinha, Pilar Azevedo, Juliana Roda, Carlos M. Farinha, and Margarida D. Amaral have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Hospital de Santa Maria, Lisbon, Portugal (DIRCLN-16JUL2014-211).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all the subjects.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All materials used will be made available upon request to the authors.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analyses were performed by VR, CR, SSR, IALS, IP, TD, SC, PA, and JR. The first draft of the manuscript was written by VR, CR, SSR, IP, and CMF. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}